New Tool for Assessing Frailty in Patients With Newly Diagnosed Multiple Myeloma
A new “frailty index” may predict overall survival for patients newly diagnosed with multiple myeloma, according to a study published in JCO Clinical Cancer Informatics...
Encorafenib Plus Binimetinib in Unresectable or Metastatic Melanoma With BRAF Mutations
This past June, encorafenib and binimetinib were approved in combination for treatment of unresectable or metastatic melanoma with a BRAF V600E...
Meeting the Challenges of Immunotherapy-Related Toxicities
In 2011, the U.S. Food and Drug Administration (FDA) approved ipilimumab, an anticytotoxic T-lymphocyte– associated antigen 4, the first checkpoint inhibitor for the treatment of advanced melanoma....
ACS Nutrition and Physical Activity Guidelines for Cancer Survivors and Outcomes After Colon Cancer Diagnosis
In a study reported in JAMA Oncology, Erin L. Van Blarigan, ScD, of the University of California, San Francisco, and colleagues found that adherence to American Cancer Society...
FDA Approves HPV Test for First-Line Cervical Cancer Screening
On July 30, 2018, Roche announced approval by the U.S. Food and Drug Administration (FDA) of its cobas HPV Test in first-line screening for cervical cancer...
More Top Stories
Risk of Breast Cancer After Negative Screening Mammography
A study reported in JAMA Oncology by Anne Marie McCarthy, PhD, of the Division of General Internal Medicine, Massachusetts General Hospital, and colleagues identified the risk of interval breast cancer after negative screening mammography, including the risk of poor-prognosis breast cancer. The...
FDA Grants Breakthrough Device Designation for Cancer Detection Liquid Biopsy
PapGene, Inc, has announced their cancer detection test has received Breakthrough Device designation from the Center for Devices and Radiological Health (CDRH) of the U.S. Food and Drug Administration (FDA). The PapGene test is a multianalyte test that uses a combination of circulating tumor DNA...
CXCR4 Antagonist Plus Eribulin in HER2-Negative Metastatic Breast Cancer
Findings in a phase I trial reported in The Lancet Oncology by Pernas and colleagues indicate activity of the combination of the CXCR4 chemokine receptor antagonist balixafortide plus eribulin (Halaven) in previously treated HER2-negative metastatic breast cancer. The CXCR4–stromal cell-derived...
8-Year Update of SOFT and TEXT Trials: Positive but Not Definitive
At the 2017 San Antonio Breast Cancer Symposium (SABCS), the International Breast Cancer Study Group (IBCSG) and its collaborators presented the 8-year updates of the key modern trials of ovarian function suppression after local treatment for young women with resected breast cancer.1 These updates...
Cardiac Monitoring in Patients With Breast Cancer
Although heart failure is an uncommon complication of breast cancer treatment, the risk may be higher in patients treated with certain types of chemotherapy and lower in younger patients, according to a study published by Henry et al in JACC: Cardiovascular Imaging. Researchers studied 16,456...
New Frontiers Being Explored in Multiple Myeloma
BEFORE TOO LONG, oncologists can expect to have an entirely new arsenal in the fight against multiple myeloma. Cutting-edge therapies on the near horizon were described in a presentation by Kenneth Anderson, MD, at the 2018 American Association of Cancer Research’s (AACR’s) inaugural conference on...
Apatinib and Oral Etoposide in Platinum-Resistant/Refractory Ovarian Cancer
In a Chinese single-center phase II study reported in The Lancet Oncology, Lan et al found a high response rate with oral apatinib plus oral etoposide in patients with platinum-resistant or refractory ovarian cancer. Study Details The study included 35 patients with progression within 6 months...
Susan Blumel, RN, BSN, and Laura J. Zitella, MS, RN, ACNP-BC, AOCN, on Managing Toxicities of Immunotherapy
